Partners Louis Lehot and Michael Kirwan published an article in Reuters Legal News titled: "The Importance of ESG for Startups: Pioneering a Sustainable Future."

Late last month, the U.S. Bureau of Ocean Energy Management (BOEM) issued an immediate stop-work order for Revolution Wind, Ørsted's $6.2 billion, 65-turbine offshore wind power project located 15 miles south of Rhode Island.

UBQ's innovative approach to sustainable materials and waste reduction has potential to make a profound impact on our environment. As we face increasing challenges related to climate change...

Brian Lucareli, Director of Foley Private Client Services (PCS) and co-chair of the Family Offices group, sits down with Nate Imfeld, Senior Counsel, Family Offices group, for a 10-minute interview...

Legislation was introduced in Congress August 2, 2012 that would prevent the Federal Reserve from designating nonbanks as systemically significant.

Foley & Lardner LLP Director of Public Affairs Katie Schoettler authored the article, "The federal response to recent banking developments – what is it and why does it matter?"...

Former Commodity Futures Trading Commission (CFTC) Commissioner Brian Quintenz was nominated to be the CFTC Chair in February 2025.

The CFPB has published for public comment, a proposed rule amending Regulation C to implement amendments to the Home Mortgage Disclosure Act.

Partners Chanley Howell and Michael Scarano, Senior Counsel Aaron Tantleff, and Associate Leeann Habte authored an article that appeared in the June 2013 issue of AHLA Connections.

A summary of the most recent published research from IBM and others on nanoscale magnetic resonance imaging.

The U.S. Food and Drug Administration (FDA) recently announced that the Agency is lifting its enforcement discretion over high-risk laboratory developed tests (LDTs).

Cosmetic companies are required to submit facility registration and product listing information on cosmetic products that they manufacture, or other procedures, including manipulation, sampling...

Diagnostic medicine is experiencing new challenges at the USPTO and the U.S. Food and Drug Administration (FDA). Under a new FDA proposal, laboratory developed test providers, previously exempt from FDA oversight, must now consider if their diagnostic test may be subject to FDA oversight, either as a moderate risk (Class II) or high-risk (Class III) device.

The long-anticipated decision by the U.S. Supreme Court regarding the constitutionality of the individual mandate portion of the Patient Protection and Affordable Care Act was issued this morning.

3D printing seems to be the rage these days in the technical and general media.

Efforts to replace the ACA with the Graham-Cassidy legislation were unsuccessful as lawmakers rushed to meet the September 30th deadline when the Senate would have lost its current reconciliation vehicle.

Last June, we held our 11th CEO/Innovators Roundtable in Boston. Boston. This two-day gathering brought together some of the most dynamic minds in health care to share ideas...

On Thursday, April 10, 2025, in its Boston office of Foley & Lardner LLP hosted and participated in a MedTech round table of investors and business leaders...

On April 15, 2013, the Supreme Court will hear oral arguments in the Myriad Genetics v. Association for Molecular Pathology litigation.

The Economist, one of the more worthy media sources these days for connecting technology to larger society, included a page on nanomedicine in its special issue, "The World in 2013." (page 128).